Anzeige
Mehr »
Sonntag, 05.07.2026 - Börsentäglich über 12.000 News
Milliardenkonkurrenten im Visier: Dieser KI-Wert gewinnt namhafte Großkunden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P3B3 | ISIN: US12591J2078 | Ticker-Symbol: CVGU
Siehe auch CSPC PHARMACEUTICAL GROUP LTD
Frankfurt
03.07.26 | 08:03
3,140 Euro
+3,29 % +0,100
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
CSPC PHARMACEUTICAL GROUP LTD ADR Chart 1 Jahr
5-Tage-Chart
CSPC PHARMACEUTICAL GROUP LTD ADR 5-Tage-Chart

Aktuelle News zur CSPC PHARMACEUTICAL GROUP LTD ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCSPC PHARMA Surges 6%+ After Entering w/AstraZeneca a Collaboration, Option and License Agreement for Development of siRNA Drugs3
DoAZ forges ever-closer ties with China's CSPC Pharma2
DoCSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SYS6043 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PLATINUM-RESISTANT OVARIAN ...2
DoCSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - IRON SUCROSE INJECTION RECEIVES MARKETING APPROVAL3
DoCSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - RECOMBINANT HERPES ZOSTER VACCINE (SYS6052) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA2
CSPC PHARMACEUTICAL GROUP LTD ADR Aktie jetzt für 0€ handeln
DoCSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL STUDY OF SYH2095 TABLETS AS A MONOTHERAPY OR IN COMBINATION REGIMENS FOR THE TREATMENT ...2
DoCSPC PHARMA, AstraZeneca Forge Collaboration, Option and License Agreement for Development of siRNA Drugs3
DoCSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - ENTERING INTO COLLABORATION, OPTION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR THE DEVELOPMENT OF SIRNA ...5
DiCSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE ADJUVANT TREATMENT OF RESECTED ...2
26.06.CSPC PHARMA Initiates Phase III Clinical Study in China for SYS6010 Combined with Enlangsubai Monoclonal Antibody for NSCLC Treatment24
26.06.CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF DRIVER GENE-NEGATIVE ...2
25.06.Dividendenbekanntmachungen (25.06.2026)8.701 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  AJISEN CHINA HOLDINGS LTD  KYG0192S1093  0,113 HKD  0,0126 EUR  ALLGAEUER BRAUHAUS AG  DE0005035505 - 2 EUR  ASYMCHEM LABORATORIES TIANJIN...
► Artikel lesen
23.06.CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME1
22.06.CSPC PHARMA (01093): FURTHER ANNOUNCEMENT - UPDATE ON DISCLOSEABLE TRANSACTION IN RELATION TO THE PROPOSED H SHARE LISTING OF CSPC INNOVATION5
18.06.CSPC PHARMA Octreotide Long-Acting Injection Approved for US Clinical Trials4
18.06.CSPC PHARMA Second Marketing Application for Idaglutide Injection Accepted by NMPA3
18.06.CSPC PHARMA Secukinumab Injection Accepted for Marketing Approval by NMPA2
18.06.CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS SECOND MARKETING AUTHORISATION APPLICATION FOR EFMEDAGLUTIDE ALFA INJECTION3
18.06.CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR SECUKINUMAB INJECTION3
18.06.CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION (SYHX2008) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.3
Weiter >>
100 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1